STOCK TITAN

Viking group discloses 9.99% Rallybio (RLYB) stake with warrant blocker

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Rallybio Corporation received an updated ownership report showing Viking Global’s group holding a significant passive stake. The Viking entities report beneficial ownership of 4,222,969 shares of Rallybio common stock, equal to 9.99% of the class, including shares underlying pre-funded warrants.

The warrants allow purchase of 3,333,388 shares at an exercise price of $0.0001 per share, but a 9.99% “Blocker” limits how many can be exercised at any time, with 28,192 warrant shares currently counted in beneficial ownership. Viking certifies the securities are not held for the purpose of changing or influencing control of Rallybio.

Positive

  • None.

Negative

  • None.

Insights

Viking discloses a capped 9.99% passive stake in Rallybio.

Viking Global and affiliated entities report beneficial ownership of 4,222,969 Rallybio common shares, or 9.99% of the class. This includes 4,194,777 shares held directly and 28,192 shares currently issuable from pre-funded warrants, all aggregated under Rule 13d-3.

The warrants cover 3,333,388 shares at an exercise price of $0.0001 per share, but a contractual “Blocker” prevents exercises that would push ownership above 9.99%. The blocker can be adjusted up to 19.99% after a 61-day notice period, which could expand effective exposure if used.

The filing is a Schedule 13G/A Amendment No. 3, with a certification that holdings are not for changing or influencing control, indicating a passive reporting posture. Actual impact on Rallybio’s trading and governance will depend on future exercises and any later changes in filing status.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G



VIKING GLOBAL INVESTORS LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Parent GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Illiquid Investments Sub-Master LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:02/17/2026
HALVORSEN OLE ANDREAS
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
Date:02/17/2026
Ott David C.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
Date:02/17/2026
Shabet Rose Sharon
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
Date:02/17/2026

Comments accompanying signature: (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).
Exhibit Information

EXHIBIT A - JOINT FILING AGREEMENT

FAQ

What ownership stake in Rallybio (RLYB) does Viking report in this Schedule 13G/A?

Viking and its affiliated entities report beneficial ownership of 4,222,969 Rallybio common shares, representing 9.99% of the outstanding class. This total includes both shares held directly and a portion of shares currently issuable under pre-funded warrants, subject to a contractual blocker.

How many Rallybio shares does Viking hold directly versus through warrants?

Viking’s group reports 4,194,777 Rallybio shares held directly and 28,192 shares counted from pre-funded warrants. The warrants cover 3,333,388 shares in total, but most are excluded from current beneficial ownership because of a 9.99% ownership blocker in the warrant terms.

What is the 9.99% ownership blocker mentioned in the Rallybio (RLYB) filing?

The warrants include a 9.99% “Blocker” that prevents Viking and related holders from exercising warrants if doing so would push their beneficial ownership above 9.99%. This cap manages reported ownership and can be increased or decreased, up to 19.99%, with 61 days’ advance notice.

How was Viking’s 9.99% Rallybio ownership percentage calculated?

The 9.99% stake is based on 42,243,774 Rallybio shares outstanding as of December 30, 2025, plus 28,192 shares Viking can currently purchase via warrants. That combined base is disclosed in Rallybio’s Schedule 14A proxy statement, which the ownership calculation explicitly references.

Does Viking indicate any intent to control Rallybio Corporation in this 13G/A?

No. The signatories certify the securities were not acquired and are not held for the purpose of changing or influencing control of Rallybio. The statement is filed on Schedule 13G/A, which is typically used for passive holdings rather than activist or control-oriented positions.

Who are the reporting persons in Viking’s Rallybio (RLYB) Schedule 13G/A Amendment No. 3?

The filing lists multiple reporting persons, including Viking Global Investors LP, several Viking Global Opportunities entities, Viking Global Opportunities Illiquid Investments Sub-Master LP, and individuals O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, all sharing voting and dispositive power over the reported shares.
Rallybio Corp

NASDAQ:RLYB

RLYB Rankings

RLYB Latest News

RLYB Latest SEC Filings

RLYB Stock Data

22.86M
4.68M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN